These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26401932)

  • 1. Levels of 17β-Hydroxysteroid Dehydrogenase Type 10 in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Various Types of Dementias.
    Kristofikova Z; Ricny J; Vyhnalek M; Hort J; Laczo J; Sirova J; Klaschka J; Ripova D
    J Alzheimers Dis; 2015; 48(1):105-14. PubMed ID: 26401932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease.
    Kristofikova Z; Ricny J; Kolarova M; Vyhnalek M; Hort J; Laczo J; Sirova J; Ripova D
    J Alzheimers Dis; 2014; 42 Suppl 3():S91-8. PubMed ID: 24670397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of 17β-hydroxysteroid dehydrogenase type 10 in CSF are not a valuable biomarker for multiple sclerosis.
    Kristofikova Z; Ricny J; Kaping D; Klaschka J; Kotoucova J; Bartos A
    Biomark Med; 2018 Dec; 12(12):1331-1340. PubMed ID: 30520659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
    Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
    J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
    Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
    Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis.
    Struyfs H; Van Broeck B; Timmers M; Fransen E; Sleegers K; Van Broeckhoven C; De Deyn PP; Streffer JR; Mercken M; Engelborghs S
    J Alzheimers Dis; 2015; 45(3):813-22. PubMed ID: 25633670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of 17β-Hydroxysteroid Dehydrogenase Type 10 and Cyclophilin D in Alzheimer's Disease.
    Kristofikova Z; Springer T; Gedeonova E; Hofmannova A; Ricny J; Hromadkova L; Vyhnalek M; Laczo J; Nikolai T; Hort J; Petrasek T; Stuchlik A; Vales K; Klaschka J; Homola J
    Neurochem Res; 2020 Apr; 45(4):915-927. PubMed ID: 31997103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
    Alexopoulos P; Guo LH; Jiang M; Bujo H; Grimmer T; Förster S; Drzezga A; Kurz A; Perneczky R
    J Alzheimers Dis; 2013; 36(2):401-8. PubMed ID: 23609762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease.
    Johansson P; Åberg D; Johansson JO; Mattsson N; Hansson O; Ahrén B; Isgaard J; Åberg ND; Blennow K; Zetterberg H; Wallin A; Svensson J
    Psychoneuroendocrinology; 2013 Sep; 38(9):1729-37. PubMed ID: 23473966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease.
    Le Bastard N; Aerts L; Sleegers K; Martin JJ; Van Broeckhoven C; De Deyn PP; Engelborghs S
    J Alzheimers Dis; 2013; 33(3):807-22. PubMed ID: 23034521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
    Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P
    J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Allergy on Immunoglobulins and Amyloid-β in the Cerebrospinal Fluid of Patients with Alzheimer's Disease.
    Sarlus H; Eyjolfsdottir H; Eriksdotter M; Oprica M; Schultzberg M
    J Alzheimers Dis; 2015; 48(2):495-505. PubMed ID: 26402013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interrelations between CSF soluble AβPPβ, amyloid-β 1-42, SORL1, and tau levels in Alzheimer's disease.
    Alexopoulos P; Guo LH; Tsolakidou A; Kratzer M; Grimmer T; Westerteicher C; Jiang M; Bujo H; Diehl-Schmid J; Kurz A; Perneczky R
    J Alzheimers Dis; 2012; 28(3):543-52. PubMed ID: 22045485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
    Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K
    J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
    J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.